A big quarterly earnings miss was the news driving down the value of Apellis Pharmaceuticals (NASDAQ: APLS) stock in the middle of the trading week. Investors didn't take this development well, and ...

Biogen Inc. (NASDAQ:BIIB) is one of the 10 Most Undervalued NASDAQ Stocks to Buy Right Now. On June 29, it was reported that ...

The pharma company plans to pause or terminate investment in most of Apellis’ legacy research programmes.

Apellis was informed of a negative trend vote on the pegcetacoplan European marketing application. More than 2.5 million people in Europe are living with geographic atrophy. Get our list of 10 ...

14 analysts have shared their evaluations of Apellis Pharmaceuticals (NASDAQ:APLS) during the recent three months, expressing a mix of bullish and bearish perspectives. The following table ...

11 analysts have shared their evaluations of Apellis Pharmaceuticals (NASDAQ:APLS) during the recent three months, expressing a mix of bullish and bearish perspectives. The table below summarizes ...

Today's biggest winners and losers in the stock market. On this episode of Stock Movers: - Biogen (BIIB) has agreed to acquire Apellis Pharmaceuticals Inc. for $5.6 billion, expanding its treatments ...

The deal includes an upfront payment plus milestone payments tied primarily to clinical and regulatory successes.

The drugmaker published its latest set of quarterly figures. Unfortunately for investors, it missed on both the top and bottom lines. Apellis unveiled those results before market hours on Tuesday, ...

Novartis and its Fabhalta may have been first to the punch in ultrarare kidney disease complement 3 glomerulopathy (C3G), but Apellis Pharmaceuticals has delivered a checkmate with a wider label and a ...

Favus Institutional Research called into question data regarding Apellis' lead therapy, Syfovre, which is the only therapy approved by the Food and Drug Administration (FDA) to treat geographic ...